So far, GLP-1 receptor agonists are only regionally registered for the treatment of obesity and there exists much inequality in access to it due to requirements for access and lack of financial coverage137,138. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.